《Npj Breast Cancer》雜志的最新年發(fā)文量為87篇。
這表明該刊在每年都會精選并發(fā)表一定數(shù)量的高質(zhì)量文章,以保持其在腫瘤學領(lǐng)域的學術(shù)影響力。
該刊聚焦于醫(yī)學-腫瘤學領(lǐng)域的前沿研究,致力于推動該領(lǐng)域新技術(shù)和新知識的傳播與應用。同時它積極鼓勵研究人員詳細發(fā)表其高質(zhì)量的實驗研究和理論成果。
該刊的平均審稿周期約為 9 Weeks 。
Npj Breast Cancer 雜志發(fā)文統(tǒng)計
文章名稱引用次數(shù)
- MONARCH 3 final PFS: a randomized study of abemaciclib as initial therapy for advanced breast cancer59
- Image analysis with deep learning to predict breast cancer grade, ER status, histologic subtype, and intrinsic subtype24
- If we build it they will come: targeting the immune response to breast cancer17
- Exploration of PET and MRI radiomic features for decoding breast cancer phenotypes and prognosis16
- 21-Gene assay as predictor of chemotherapy benefit in HER2-negative breast cancer15
- Are all cyclin-dependent kinases 4/6 inhibitors created equal?15
- Phase II study of ruxolitinib, a selective JAK1/2 inhibitor, in patients with metastatic triple-negative breast cancer15
- Simultaneous defeat of MCF7 and MDA-MB-231 resistances by a hypericin PDT-tamoxifen hybrid therapy13
- Cyclin E1 and Rb modulation as common events at time of resistance to palbociclib in hormone receptor-positive breast cancer12
- E2112: randomized phase iii trial of endocrine therapy plus entinostat/placebo in patients with hormone receptor-positive advanced breast cancer12
國家/地區(qū)發(fā)文量
- USA119
- England21
- Italy19
- Canada16
- Australia14
- CHINA MAINLAND12
- Belgium11
- GERMANY (FED REP GER)11
- Netherlands10
- France9